Neurocrine Biosciences Inc. (NBIX)
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indications like Alzheimer's Disease. There are several other shots on goal in targeting the Schizophrenia patient populations using luvadaxistat and others. The global Schizophrenia Drugs Market is forecasted to reach $9.46 billion by 2030.
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5pt placebo-adjusted reduction missing the double-digit target the Street wanted to see. Management remains optimistic about '568, planning Phase III trials, but it seems optimistic to think that Phase III results are likely to be good enough to make '568 truly competitive.
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Neurocrine's schizophrenia drug meets main goal in mid-stage study
Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way
Ingrezza sales are on the rise, with a 32% increase in sales in Q2'24, and there is still an attractive runway of growth ahead for the drug. The Phase II results of '845 in major depressive disorder exceeded expectations, potentially adding over $1B to the revenue pool and positioning it as a potential future rival to Spravato. The upcoming Phase II readout for '568 (an M4 agonist) in schizophrenia is a potentially significant value-creation opportunity, but it will likely require a double-digit improvement in PANSS.
Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.95 per share a year ago.
Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine's Growing Sales, Profits Attracting Big Money
Sales and profits have been rocketing upwards for Neurocrine Biosciences, Inc. (NBIX), and a recent regulatory approval should continue that trend.
Neurocrine founder-CEO Gorman to retire in October
Neurocrine Biosciences CEO Kevin Gorman will retire on Oct. 11 after three decades with the company that he founded and will be succeeded by insider Kyle Gano.
